- Report
- February 2024
- 175 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- January 2024
- 200 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- April 2024
- 175 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- February 2024
- 150 Pages
Global
From €4128EUR$4,250USD£3,561GBP
- Report
- November 2023
- 135 Pages
Global
From €3885EUR$4,000USD£3,351GBP
- Report
- April 2023
- 115 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Report
- January 2022
- 419 Pages
Global
From €9227EUR$9,500USD£7,960GBP
- Report
- August 2022
- 120 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Report
- December 2022
- 210 Pages
Global
From €5565EUR$5,730USD£4,801GBP
Glycopyrronium is a medication used to treat chronic obstructive pulmonary disease (COPD). It is a long-acting anticholinergic bronchodilator, which works by relaxing the muscles in the airways, allowing air to flow more freely. It is typically used in combination with other medications to treat COPD, such as inhaled corticosteroids and long-acting beta-agonists. Glycopyrronium is available in both oral and inhalation forms, and is typically prescribed for long-term use.
Glycopyrronium is a relatively new medication, and is not yet widely used in the treatment of COPD. However, it is becoming increasingly popular due to its effectiveness and long-term safety profile. It is also relatively inexpensive compared to other COPD medications, making it an attractive option for many patients.
Some of the companies in the Glycopyrronium market include GlaxoSmithKline, Boehringer Ingelheim, and Mylan. Show Less Read more